Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Change in Acquisitions & Divestments data on file, last reported at $272.8 million in Q2 2026.

• Quarterly Change in Acquisitions & Divestments fell 17.95% year-over-year to $272.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 16.94% YoY) and the FY2025 annual result came in at $1.8 billion, up 14.67% from the prior year.
• Change in Acquisitions & Divestments improved to $272.8 million in Q2 2026, from $213.2 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $723.4 million in Q3 2025 to a low of $213.2 million in Q1 2026.
• A 5-year average of $424.7 million and a median of $403.9 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments soared 107.49% — and 2026, when it slumped 59.34%.
• Tracing ALNY's Change in Acquisitions & Divestments over 5 years: stood at $604.7 million in 2022, then sank by 39.84% to $363.8 million in 2023, then rose by 21.77% to $443.0 million in 2024, then tumbled by 49.88% to $222.0 million in 2025, then rose by 22.86% to $272.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $272.8 million (Q2 2026), $213.2 million (Q1 2026), and $222.0 million (Q4 2025), per Business Quant data.